In: Cancers, 2021, vol. 13, no. 9, p. 15
Axillary dissection is a highly mobile procedure with severe lymphatic consequences. The off-label application of fibrin sealants in the axilla, with the sole aim to eliminate dead space and to provoke sealing of the disrupted lymphatic vessels at the end of axillary dissection, is an experimental procedure to reduce lymphatic morbidity. The aim of our systematic review and meta-analysis is to ...
|
In: Archives of Gynecology and Obstetrics, 2015, vol. 291, no. 6, p. 1387-1394
|
In: Gynäkologische Endokrinologie, 2015, vol. 13, no. 2, p. 126-134
|
In: Breast Cancer Research and Treatment, 2015, vol. 150, no. 2, p. 363-371
|
In: Breast Cancer Research and Treatment, 2015, vol. 149, no. 2, p. 449-460
|
In: Breast Cancer Research and Treatment, ///-
|
In: Cancers, 2020, vol. 12, no. 10, p. 23 p
Triple-negative breast cancer (TNBC) is a heterogeneous disease that lacks effective therapeutic options. In this study, we profile eighteen TNBC cell lines for their sensitivity to the anti-proliferative action of all-trans retinoic acid (ATRA). The only three cell lines (HCC-1599, MB- 157 and MDA-MB-157) endowed with ATRA-sensitivity are characterized by genetic aberrations of the NOTCH1-gene,...
|
In: The breast, 2020, vol. 52, p. 110-115
Background: Corona Virus Disease 19 (COVID-19) had a worldwide negative impact on healthcare systems, which were not used to coping with such pandemic. Adaptation strategies prioritizing COVID-19 patients included triage of patients and reduction or re-allocation of other services. The aim of our survey was to provide a real time international snapshot of modifications of breast cancer...
|
In: Frontiers in immunology, 2019, vol. 10, p. 1594
Human cancer cells operate a variety of effective molecular and signaling mechanisms which allow them to escape host immune surveillance and thus progress the disease. We have recently reported that the immune receptor Tim-3 and its natural ligand galectin-9 are involved in the immune escape of human acute myeloid leukemia (AML) cells. These cells use the neuronal receptor latrophilin 1...
|
In: Familial Cancer, 2014, vol. 13, no. 1, p. 99-107
|